BLOOD CYTOKINE PROFILE AND LESION SITE REPAIR IN DYNAMICS OF EXPERIMENTAL THERMAL TRAUMA AFTER LOCAL AND SYSTEMIC MELATONIN ADMINISTRATION

Burn injuries are one of the key medical and social problems. Despite the significant achievements in combustiology, the slow healing and the appearance of infection are the key problems in burn patients, which lead to a longer hospitalization period, to reduction of life quality and to emotional disorders. Up to 70% of all complications after thermal trauma (TT) are connected with infection – first of all, pneumonia, infections of urinal tract. The forming of infectious complications, including sepsis, after TT is associated with excessive immunosuppressive reactions, as compensation for a long, stable proinflammatory response, in particular, owing to hyperproduction and effects of IL-10, IL-4, TGF-β. Aim: to study the influence of systemic and local usage of MT with original dermal film (DF) on reparation and serum cytokine concentration indicators in dynamics of experimental TT. The study was conducted using 84 rats – males of Wistar line, which were divided randomly into 4 groups: 1st group (n = 12) – intact monitoring, 2nd group (n = 30) – animals with TT, 3rd group (n = 21) – animals with TT and DF with MT use on the region of burn, 4^th group (n = 21) – animals with TT and intraperitoneal injection of MT. To model TT of IIIA degree and relative area 3,5%, isolated skin area of interscapular area was immersed in distilled water at a temperature of 98-99 °С at 12 s. The DF with MT (at a concentration of 0.005 g/g) on 12 sm2 – area in 3rd group was used daily for 5 days. The MT was injected intraperitoneally daily at the dose of 10 mg/kg for 5 days. The wound area was calculated, the interleukin-4 (IL-4), tumor necrosis factor alpha (TNFα), interferon-gamma (IFNγ) were determined in serum on 5^th,10^th and 20th day from the moment of TT induction in each group. During experimental TT in dynamic monitoring from 5^th to 20^th day the absolute and relative areas of wound defect are reduced, because of that the epithelization speed and its part of area reduction are progressively increasing, on 5^th,10^th and 20^th day the concentration of TNFα and IL-4 in serum is increasing with maximum values on 10th day of monitoring. Local usage of MT in DF during TT accelerates the healing of burn wound and lowers the TNFα and IL-4 concentration in serum on 5^th, 10^th and 20^th day. Intraperitoneal use of MT during TT accelerates the healing of burn wound and lowers the TNFα and IL-4 concentration in serum on 5^th and 20^th day. The reparation accelerating effect of MT during TT is more expressed in locale usage in DF rather than using intraperitoneal injection. 

1. Boutin J.A., Ferry G. Is there sufficient evidence that the melatonin binding Site MT3 is Quinone Reductase 2? J. Pharmacol. Exp. Ther., 2019, no. 368, pp. 59–65. doi:10.1124/jpet.118.253260.

2. Dong K., Goyarts E., Rella A., Pelle E., Wong Y.H., Pernodet N. Age associated decrease of MT-1 melatonin receptor in human dermal skin fibroblasts impairs protection against UV-induced DNA damage. Int. J. Mol. Sci., 2020, Vol. 21, no. 1, pp. E326. doi: 10.3390/ijms21010326.

3. Favero G., Franceschetti L., Bonomini F., et al. Melatonin as an anti-inflammatory agent modulating inflammasome activation. Int. J. Endocrinol., 2017, no. 2017, pp. 1835195. doi: 10.1155/2017/1835195.

4. Galano A., Tan D.X., Reiter R.J. Melatonin: a versatile protector against oxidative DNA damage. Molecules, 2018, no. 23, pp. E530. doi:10.3390/molecules23030530.

5. Hardeland R. Aging, melatonin, and the pro- and anti-inflammatory networks. Int. J. Mol. Sci., 2019, Vol. 20, no. 5, pii: 1223. doi:10.3390/ijms20051223.

6. Lateef Z., Stuart G., Jones N., Mercer A., Fleming S., Wise L. The cutaneous inflammatory response to thermal burn injury in a murine model. Int. J. Mol. Sci., 2019, Vol. 20, no. 3, pii: E538. doi: 10.3390/ijms20030538

7. Loynes C.A., Lee J.A., Robertson A.L., Steel M.J., Ellett F., Feng Y., Levy B.D., Whyte M.K., Renshaw S.A. PGE2 production at sites of tissue injury promotes an anti-inflammatory neutrophil phenotype and determines the outcome of inflammation resolution in vivo. Sci. Adv., 2018, no. 4, pp. eaar8320. doi:10.1126/sciadv.aar8320.

8. Mayo J.C., Aguado A., Cernuda-Cernuda R., Alvarez-Artime A., Cepas V., Quiros-Gonzalez I., et al. Melatonin uptake by cells: an answer to its relationship with glucose? Molecules, 2018, no. 23, pp. e1999. doi:10.3390/molecules23081999.

9. Nishiguchi T., Ito I., Lee J.O., Suzuki S., Suzuki F., Kobayashi M. Macrophage polarization and MRSA infection in burned mice. Immunol. Cell Biol, 2017, Vol. 95, no. 2, pp. 198-206. doi:10.1038/icb.2016.84.

10. Osikov M.V., Simoyan E.V., Saedgalina O.T. Effect of erythropoietin on the quantitative composition and apoptosis of lymphocytes of peripheral blood in dynamic of experimental thermal injury. Russian Journal of Immunology, 2016, Vol. 10 (19), no. 2-1, pp. 479-481. (In Russ.)

11. Osikov M.V., Simoyan E.V., Saedgalina O.T. Erythropoietin influence in trancedermal film on the indicators of immune status of rat in experimental thermal injury. Experimental and Clinical Pharmacology, 2018, Vol. 81, no. 8, pp. 13-18. (In Russ.)

12. Osikov M.V., Simoyan E.V., Saedgalina O.T. Influence of melatonin on innate immunity in experimental desynchronosis under led lighting conditions. Russian Journal of Immunology, 2015, Vol. 9 (18), no, 3-1, pp. 154-156. (In Russ.)

13. Saavedra P.A., deBrito E.S., Areda C.A., Escalda P.M., Galato D. Burns in the Brazilian Unified Health System: a review of hospitalization from 2008 to 2017. Int. J. Burns Trauma, 2019, Vol. 9, no. 5, pp. 88-98.

14. Slominski A.T., Semak I., Fischer T.W., Kim T.-K., Kleszczyński K., Hardeland R., Reiter R.J. Metabolism of melatonin in the skin: why is it important? Experimental Dermatology, 2017, Vol. 26, no. 7, pp. 563–568. doi:10.1111/exd.13208.

15. Wang Y., Beekman J., Hew J., Jackson S., Issler-Fisher A.C., Parungao R., Lajevardi S.S., Li Z., Maitz P.K.M. Burn injury: challenges and advances in burn wound healing, infection, pain and scarring. Adv. Drug Deliv. Rev., 2018, no. 123, pp. 3-17. doi:10.1016/j.addr.2017.09.018.